Bactericidal synergism between phage and antibiotics: A combination strategy to target multidrug-resistant Klebsiella pneumoniae in vitro and in vivo
European Journal of Pharmaceutics and Biopharmaceutics · 2025
DOI: 10.1016/j.ejpb.2025.114759 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2025. Verfasst von Shuxian Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Food Science and Technology, Shanghai Ocean University, Shanghai 201306, China. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, Anti-Bacterial Agents, Drug Resistance, Multiple, Bacterial, Bacteriophages. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Ministry of Science and Technology of the People's Republic of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Bacteriophages have reemerged to potentially replace or complement the role of antibiotics, as bacterial viruses have the ability to inactivate pathogens. However, certain intrinsic limitations of phages overshadow their clinical application, particularly their narrow host spectrum and rapid development of resistance upon treatment. This study aimed to explore the synergistic antimicrobial effect of phage combined with antibiotics against Klebsiella pneumoniae. The time-killing experiments in vitro showed that phage and gentamicin combination displayed synergistic bactericidal activity, leading to a reduction in the minimum inhibitory concentration of gentamicin. Furthermore, the phage HS106/gentamicin combination significantly inhibited biofilm formation and eliminated mature biofilms. On the other hand, phage treatment for 2 h before gentamicin treatment produced better synergistic inhibitory effect. The use of phage followed by gentamicin can effectively inhibit the efflux effect. Surprisingly, the phage HS106/gentamicin combination still exhibited antimicrobial activity against phage-resistant mutants and double-resistant mutants. Finally, the phage HS106/gentamicin combination significantly increased the survival rate of zebrafish infected with K. pneumoniae, indicating its excellent bactericidal activity in vivo. Overall, the phage HS106/gentamicin combination may provide a promising approach for treating infections caused by high-level multidrug-resistant K. pneumoniae.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Food Science and Technology, Shanghai Ocean University, Shanghai 201306, China.
- College of Food Science and Technology, Shanghai Ocean University, Shanghai 201306, China; Shanghai Engineering Research Center of Aquatic-Product Processing & Preservation, Shanghai 201306, China.
- College of Food Science and Technology, Shanghai Ocean University, Shanghai 201306, China; Shanghai Engineering Research Center of Aquatic-Product Processing & Preservation, Shanghai 201306, China; Laboratory of Quality…
Förderung
- Ministry of Science and Technology of the People's Republic of China
- National Key Research and Development Program of China
Zitieren
APA
Wang, S., Fan, W., Jin, R., Lan, W., Zhao, Y., & Sun, X. (2025). Bactericidal synergism between phage and antibiotics: A combination strategy to target multidrug-resistant Klebsiella pneumoniae in vitro and in vivo. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2025.114759
Vancouver
Wang S, Fan W, Jin R, Lan W, Zhao Y, Sun X. Bactericidal synergism between phage and antibiotics: A combination strategy to target multidrug-resistant Klebsiella pneumoniae in vitro and in vivo. European Journal of Pharmaceutics and Biopharmaceutics. 2025. doi:10.1016/j.ejpb.2025.114759
BibTeX
@article{Wang2025,
author = {Wang, Shuxian and Fan, Wenqi and Jin, Rulin and Lan, Weiqing and Zhao, Yong and Sun, Xiaohong},
title = {Bactericidal synergism between phage and antibiotics: A combination strategy to target multidrug-resistant Klebsiella pneumoniae in vitro and in vivo},
journal = {European Journal of Pharmaceutics and Biopharmaceutics},
year = {2025},
doi = {10.1016/j.ejpb.2025.114759}
}
EUVIMED